ENTRY       D05123                      Drug
NAME        Nasaruplase beta (USAN/INN);
            Prolyse (TN)
FORMULA     C2031H3121N585O601S31
EXACT_MASS  46313.2981
MOL_WEIGHT  46343.0863
SEQUENCE    SNELHQVPSN CDCLNGGTCV SNKYFSNIHW CNCPKKFGGQ HCEIDKSKTC YEGNGHFYRG
            KASTDTMGRP CLPWNSATVL QQTYHAHRSD ALQLGLGKHN YCRNPDNRRR PWCYVQVGLK
            PLVQECMVHD CADGKKPSSP PEELKFQCGQ KTLRPRFKII GGEFTTIENQ PWFAAIYRRH
            RGGSVTYVCG GSLISPCWVI SATHCFIDYP KKEDYIVYLG RSRLNSNTQG EMKFEVENLI
            LHKDYSADTL AHHNDIALLK IRSKEGRCAQ PSRTIQTICL PSMYNDPQFG TSCEITGFGK
            ENSTDYLYPE QLKMTVVKLI SHRECQQPHY YGSEVTTKML CAADPQWKTD SCQGDSGGPL
            VCSLQGRMTL TGIVSWGRGC ALKDKPGVYT RVSHFLPWIR SHTKEENGLA L
            (Disulfide bridge: 11-19, 13-31, 33-42, 50-131, 71-113, 102-126, 148-279, 189-205, 197-268, 293-362, 325-341, 352-380; Glycosylation site: 18, 302)
  TYPE      Peptide
CLASS       Blood modifier agent
             DG01950  Antithrombotic agent
              DG01707  Fibrinolytic
               DG01701  Urokinase-type plasminogen activator
REMARK      Chemical structure group: DG01700
EFFICACY    Fibrinolytic, Thrombolytic, Stroke treatment, Urokinase plasminogen activator (u-PA)
COMMENT     urokinase plasminogen activator (u-PA) [HSA:5328] [KO:K01348] [EC:3.4.21.73]
            Treatment of acute ischemic stroke
INTERACTION  
STR_MAP     map07049  Antithrombosis agents
BRITE       Drug groups [BR:br08330]
             Blood modifier agent
              DG01950  Antithrombotic agent
               DG01707  Fibrinolytic
                DG01701  Urokinase-type plasminogen activator
                 DG01700  Nasaruplase
                  D05123  Nasaruplase beta
            Drug groups [BR:br08330]
             Blood modifier agent
              DG01950  Antithrombotic agent
               DG01707  Fibrinolytic
                DG01701  Urokinase-type plasminogen activator
                 DG01700  Nasaruplase
DBLINKS     CAS: 136653-69-5
            PubChem: 47206848
///
